Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine A for unexplained recurrent miscarriage
ChiCTR2100046724Phase 4Not yet recruiting
- Sponsor
- Taizhou People's Hospital
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cyclosporine in recurrent miscarriage (RPL) (2 arms), sponsored by Taizhou People's Hospital. Primary endpoint: Cervical opening. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
cyclosporine
03
Conditions
recurrent miscarriage (RPL)
Beyond the preview
Go deeper on ChiCTR2100046724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046724.